Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Ignace Vergote 1 , Antonio Gonzalez-Martin 2 , Domenica Lorusso 3 , Charlie Gourley 4 , Mansoor Raza Mirza 5 , Jean-Emmanuel Kurtz 6 , Aikou Okamoto 7 , Kathleen Moore 8 , Frédéric Kridelka 9 , Iain McNeish 10 , Alexander Reuss 11 , Bénédicte Votan 12 , Andreas du Bois 13 , Sven Mahner 14 , Isabelle Ray-Coquard 15 , Elise C Kohn 16 , Jonathan S Berek 17 , David S P Tan 18 , Nicoletta Colombo 19 , Rongyu Zang 20 , Nicole Concin 21 , Dearbhaile O'Donnell 22 , Alejandro Rauh-Hain 23 , C Simon Herrington 4 , Christian Marth 24 , Andres Poveda 25 , Keiichi Fujiwara 26 , Gavin C E Stuart 27 , Amit M Oza 28 , Michael A Bookman 29 , participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines.
The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials.
Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting.
Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.